Hepion Pharmaceuticals (NASDAQ:HEPA – Get Free Report) is expected to issue its resultson Wednesday, October 14th. Analysts expect the company to post earnings of ($200.00) per share for the quarter.
Hepion Pharmaceuticals (NASDAQ:HEPA – Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($200.00) by $199.92.
Hepion Pharmaceuticals Trading Up 2.9%
NASDAQ:HEPA opened at $0.12 on Tuesday. The company has a 50-day moving average price of $0.08 and a 200-day moving average price of $0.07. Hepion Pharmaceuticals has a 12 month low of $0.03 and a 12 month high of $0.13. The stock has a market cap of $1.41 million, a price-to-earnings ratio of -0.03 and a beta of 1.52.
About Hepion Pharmaceuticals
Hepion Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for chronic liver diseases and certain cancers. The company’s research has centered on rencofilstat, also known as CRV431, an orally administered cyclophilin inhibitor designed to address disease pathways involved in liver injury, fibrosis and tumor development.
Hepion has investigated rencofilstat in conditions including metabolic dysfunction-associated steatohepatitis (formerly known as nonalcoholic steatohepatitis), chronic hepatitis B and hepatocellular carcinoma.
Read More
- Five stocks we like better than Hepion Pharmaceuticals
- Salesforce Just Got a Rare Double Upgrade—What Changed?
- OpenAI’s Revenue Scare Could Be a Big Opportunity for Investors
- China Still Dominates Rare Earths—These 3 U.S. Companies Could Benefit
- 3 REITs That May Win in a Higher Interest Rate Environment
Receive News & Ratings for Hepion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hepion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
